Ill babies are more likely to be transfused than any other patients
The special care baby unit presents unique problems for the physician caring for ill, newborn infants. These infants, both mature and preterm, are more likely to be transfused with blood products than any other group of patients.
The indications for tranfusion and the techniques used by the blood bank to provide for these needs have changed appreciably during recent years.
Exchange transfusion
Exchange transfusion for haemolytic disease of the newborn in a white baby of 31 weeks' gestation. Pigmentation caused by phototherapy. Haemoglobin concentration was 38 g/l at delivery and three double volume exchanges were carried out. Infant now well and 6 years old.
The main indication for exchange transfusion in the neonate in the United Kingdom is to prevent the kernicterus caused by a rapidly rising bilirubin concentration. Newborn infants, particularly those born prematurely, are susceptible to the dangers of hyperbilirubinaemia mainly because of the inability of the immature liver to deal with the breakdown products of haemoglobin. Any extra haematological stress can result in a further increase in the bilirubin concentration and the development of kernicterus unless treated promptly.
There are many cases of neonatal jaundice, but the most common and clinically important is haemolytic disease of the newborn. In recent years the rate of exchange transfusion for hyperbilirubinaemia has decreased, mainly for three reasons: (1) Since the introduction of immunoprophylaxis with anti-Rh immunoglobulin, the number of cases of haemolytic disease has fallen considerably (see Haemolytic disease ofthe newborn and its prevention).
(2) Successful intrauterine correction of anaemia is now carried out before delivery by transfusing red cells that are not affected by the mother's immune antibody.
(3) Other methods of preventing kernicterus, such as intensive phototherapy after delivery, are now used successfully.
Intrauterine transfusions to correctfetal anaemia
Assessment of the fetus at risk is made from the history, quantitation of the mother's antibodies, the bilirubin concentration of amniotic fluid and, ultimately, fetal blood sampling.
Fetal blood sampling and intrauterine transfusion can be carried out as early as 18 weeks' gestation. Seriously affected fetuses may receive a series of tranfusions at two to four week intervals, depending on the rate of fall of the haemoglobin concentration and the need to prevent or revert hydrops. Group 0 red cells carrying blood group antigens that do not react with the maternal antibody are used, with a packed cell volume of about 0-70 to achieve the minimum total volume load and the maximal correction of anaemia. Transfusions are given intravascularly (for immediate correction) and these may be combined with intraperitoneal administration (when Haemolytic disease of the newborn caused by antibodies other than anti-D After anti-D antibody, anti-c and anti-Kell are next in importance. Haemolytic disease as a result of anti-c may be severe enough to cause fetal hydrops if appropriate measures are not taken. That caused by anti-Kell is rare but can be severe and rapidly fatal early in gestation. The criteria for its assessment are somewhat different from those for haemolytic disease caused by anti-D, because it is thought that the antibody causes suppression of erythropoiesis in the fetus rather than just red cell destruction. As a consequence, the bilirubin concentration in the amniotic fluid may be low in relation to the severity of the anaemia. Management should comprise early fetal blood sampling and Kell grouping and regular ultrasonography if immediate transfusion is not indicated.
ABO incompatibility
The chance of ABO incompatibility is 1:5, but severe ABO haemolytic disease occurs in only about 1:3000 births. Mild disease occurs in about 1:150 births. Less than 5% of affected babies need phototherapy and only rarely is exchange transfusion required.
The diagnosis of ABO haemolytic disease is usually made in mature infants who are not anaemic and who develop jaundice during the first 24 hours of life. Characteristically the blood film contains large numbers of spherocytes, the mother is group 0 with IgG anti-A or anti-B antibodies (lysins), and the baby's blood group is A or B. The direct antiglobulin test may be negative or weakly positive. These infants can develop jaundice severe enough to lead to kernicterus.
It is particularly important to be aware of the possibility of ABO incompatibility, because as early discharge from maternity units becomes more common, healthy mature babies can develop dangerous concentrations of bilirubin at home. If phototherapy does not control the jaundice exchange transfusion with group 0 red cells-ideally suspended in group AB plasma-will be necessary.
Complications associated with exchange transfusions
Mortality from treatment with blood components in neonates is low, and most transfusion related deaths are associated with exchange transfusions. * Metabolic complications that have been reported both during and after transfusion are broadly similar to those encountered in adults. They include hypoglycaemia (which is exaggerated in preterm infants who are hypoglycaemic to start with), hyperkalaemia, and hypocalcaemia. * Cardiac and vascular complications may also occur; careful monitor'ng of input and output during exchange is mandatory to avoid acute hypervolaemia, and aliquots of 5-10 ml should be used. There is no point in carrying out more than a double volume exchange, as this will remove the maximum bilirubin and replace most of the sensitised red cells with cells unaffected by the maternally derived antibody. * Hypothermia as a result of not warming the blood properly may cause fatal cardiac arrhythmia. * Air embolism has been reported during exchange transfusion. This is caused by negative pressure occurring in the umbilical vein that results in air entering the exchange transfusion system. Exchange transfusion should always be carried out through the umbilical vein taking care not to damage vessels. The packed cell volume of transfused blood should be no more than 0 50 to avoid hyperviscosity, as the portal vein may thrombose leading to portal hypertension and varices in the second year of life. The umbilical artery should be avoided, as spasm can lead to ischaemia of the lumbar spinal cord and paralysis of the lower limbs. In recent years the survival of extremely small infants has improved, and those that are anaemic benefit from transfusion. It is essential to compare the actual concentration of haemoglobin with the expected concentration in a premature infant of similar birth weight and age. An important cause of anaemia is iatrogenic blood letting.
The haemoglobin concentration falls on average by 10 g/ 1/week from the second to the eighth week of life. It may fall naturally during this time to 70 g/l, and in an otherwise healthy premature infant this should cause no concern. A blood transfusion given solely on the basis of haemoglobin concentration is likely to be one of a series; the first will increase the concentration of haemoglobin A, shift the oxygen dissociation curve, and increase delivery of oxygen to the tissues. This will then depress production of red cells, and the concentration will fall even more before erythropoiesis is reactivated by tissue anoxia.
An important indication for transfusion is failure to achieve the expected daily weight gain. Regular transfusion in premature infants will result in improved weight gain among those who are lagging behind the expected average weight.
Clinical anaemia can be associated with a haemoglobin concentration as high as 105 g/l, emphasising that that measurement alone is no indication for giving or withholding transfusion. The physician will therefore have to make the decision using clinical judgment. A few simple guidelines should be instituted that will result in only essential transfusions being given:
(1) Record carefully all blood taken, and if 5-10% of the blood volume is removed over a short time replace by packed red cells.
(2) Measure haemoglobin concentration regularly. (3) Do not transfuse because of haemoglobin concentration alone.
(4) Evaluate weight gain, fatigue while feeding, tachypnoea, tachycardia, and hypoxia.
(5) Remember that infants with cardiac or pulmonary disease that is reducing the arterial oxygen saturation may need to have the haemoglobin concentration maintained in the range 160-170 g/l to ensure sufficient differential between arterial and venous oxygen tensions.
Complications of blood transfusion in premature neonates
In addition to those metabolic and haemodynamic complications that were described in association with exchange transfusion, there are some special complications that arise because of the neonate's immaturity, such as graft versus host disease and transmission of infection.
Transmission ofinfection (see Infectious complications oftransfusion)
Post-transfusion hepatitis is probably the most common and serious problem associated with transfusion of blood and blood products. Albumin Human albumin 4 5% is often used in the delivery room to resuscitate neonates in shock who are presumed to have had an episode of acute blood loss. Its use is justified because the baby's blood group is not yet known and it is necessary to give optimum treatment promptly with the least hazard; albumin carries no risk of transmitting viral infection (see Human albumin solutions).
Fresh frozen plasma
Aliquots of 50 ml fresh frozen plasma are provided by the Regional Blood Transfusion Service for the treatment of the coagulopathy that complicates many neonatal conditions. These contain all the procoagulation factors (including V and VIII) that deteriorate during storage as well as naturally occurring anticoagulants, immunoglobulins, and albumin.
Platelets and granulocytes (see Platelet and granulocyte transfusion) * Platelets -The most common cause of thrombocytopenia in the newborn is disseminated intravascular coagulation associated with infection. One unit of platelet concentrate is usually enough to treat any thrombocytopenic condition, and the volume can be reduced further if necessary.
Immune thrombocytopenia needs special consideration. Maternal IgG antiplatelet antibody crosses the placenta and can cause thrombocytopenia in the fetus and neonate. Spontaneous haemorrhage does not occur in the fetus. The main danger is a traumatic delivery, and if it is known that the fetus is or may be -thrombocytopenic elective caesarean section may be planned. Platelet transfusion is of limited value, but high doses of IgG given intravenously to the mother before delivery or to the neonate after birth will usually cause an increase in the number of circulating platelets.
Alloimmune neonatal thrombocytopenia, which is analogous to haemolytic disease of the newborn, is caused by the formation by the mother of antibodies to a platelet antigen that the fetus has inherited from the father; the specificity of the antibody is almost always anti-PI'. The antibody (IgG) crosses the placenta and causes profound thrombocytopenia in the fetus. Mortality is about 14% (mainly caused by intracranial haemorrhage), and those who survive may be severely disabled. In fetuses known to be at risk early fetal blood sampling to estimate the platelet count should be carried out and weekly transfusions of P1 (Al negative) platelets given as indicated until the fetus is mature enough to be delivered. In an emergency or if the platelet antibody has not been identified washed maternal platelets can be used. * Granulocytes-Severely infected neonates may develop profound neutropenia and because of the general immaturity of the immune system may benefit from transfusions of white cells, together with appropriate antibiotics. In the United Kingdom some paediatricians advise routine granulocyte transfusions in ill, infected neonates regardless of the white cell count in view ofthe impaired function ofneutrophils iri the neonatal period.
ANY QUESTIONS Does resistance to giardiasis occur and ifso by what mechanism?
Several observations, including the low rate of symptomatic disease in long term residents of an endemic area compared with short term visitors,' suggest that at least partial protective immunity leading to a degree of resistance may develop to Giardia lamblia. Probably, however, development of immunity requires long term exposure to the infection. The components of immunity are both cellular and humoral.2 The latter is mediated through a systemic antibody and a specific local antigiardia secretory IgA response. The value of this is illustrated by the increased susceptibility to giardiasis of patients with X linked hypogammaglobulinaemia, common variable immunodeficiency, and selective IgA deficiency. The cellular response is thought to be important in the coordination of antibody production and in engaging specific antigiardia cytotoxicity. Its importance is illustrated by the failure of patients with AIDS to mount an adequate immune response to the parasite.-P NATHWANI, registrar in infectious diseases, Glasgow
